EP4081181A1 - Extraits végétaux destinés au traitement d'une vascularité accrue du visage - Google Patents

Extraits végétaux destinés au traitement d'une vascularité accrue du visage

Info

Publication number
EP4081181A1
EP4081181A1 EP20807385.8A EP20807385A EP4081181A1 EP 4081181 A1 EP4081181 A1 EP 4081181A1 EP 20807385 A EP20807385 A EP 20807385A EP 4081181 A1 EP4081181 A1 EP 4081181A1
Authority
EP
European Patent Office
Prior art keywords
extract
cosmetic
pharmaceutical formulation
alpinia officinarum
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20807385.8A
Other languages
German (de)
English (en)
Inventor
Nahid Amini
Christina ÖSTERLUND
Michele Leonardi
Virginie LAFON-KOLB
Ia KHMALADZE
Lene VISDAL-JOHNSEN
Susanne FABRE
Nina HRAPOVIC
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oriflame Cosmetics Ag
Original Assignee
Oriflame Cosmetics Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oriflame Cosmetics Ag filed Critical Oriflame Cosmetics Ag
Publication of EP4081181A1 publication Critical patent/EP4081181A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9062—Alpinia, e.g. red ginger or galangal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/005—Preparations for sensitive skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
    • A61K36/704—Polygonum, e.g. knotweed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom

Definitions

  • the present invention provides an extract of Alpinia officinarum for the treatment of increased facial vascularity.
  • the present invention further provides a cosmetic or pharmaceutical formulation for use in the treatment of increased facial vascularity, and a method for production of the formulation.
  • Rosacea is a common, but poorly understood, long-term, chronic skin condition that occurs mainly on the face, typically on the nose, cheeks and forehead. The causes of rosacea are unknown and there is currently no cure.
  • Rosacea is a relapsing condition, which means that a patient may experience periods of time where the symptoms lessen or disappear altogether, and then the symptoms return.
  • rosacea There are four subtypes of rosacea including: erythematotelangiectactic rosacea (ETR) which is associated with facial redness, flushing and visible blood vessels; papulopustular rosacea which is associated with acne-like breakouts; rhinophyma which is associated with thickening of the skin on the nose; and ocular rosacea which is associated with symptoms on the eye area.
  • ETR erythematotelangiectactic rosacea
  • papulopustular rosacea which is associated with acne-like breakouts
  • rhinophyma which is associated with thickening of the skin on the nose
  • ocular rosacea which is associated with symptoms on the eye area.
  • Rosacea can be controlled to some degree with long term treatment using conventional medications. However, the changes in appearance caused by rosacea can have a significant psychological impact on the patient, such as for example causing a loss in confidence.
  • KLKs human kallikrein-related peptidases
  • KLK5 kallilkrein-5
  • KLK7 kallikrein-7
  • KLK5 kallikrein-5
  • these peptides In lesional rosacea skin, kallikrein-5 (KLK5) levels are increased, leading to increased levels of both LL- 37 and its proteolytic fragments.
  • KLK5 levels and LL-37 and its proteolytic fragments In addition to the increased abundance of KLK5 levels and LL-37 and its proteolytic fragments, these peptides also differ from those found in normal individuals. Unlike normal LL-37 peptide fragments, these abnormal peptides control functions, such as leukocyte chemotaxis, angiogenesis, and expression of extracellular matrix components.
  • the increased levels of LL-37 and other peptides induce the clinical manifestations seen in rosacea, including inflammation and increased facial vascularity.
  • a cosmetic or pharmaceutical formulation for use in the treatment of rosacea with improved efficacy compared to conventional medications.
  • a cosmetic or pharmaceutical formulation which is capable of blocking the activity or inhibiting the production of kallikrein-5 (KLK5).
  • KLK5 kallikrein-5
  • the formulation should also reduce and/or prevent the formation of LL-37 and abnormal peptide fragments, thereby inhibiting a major cascade of inflammation that has been found to be correlated with major clinical findings in rosacea.
  • Alpinia officinarum also known as lesser galangal, is indigenous to Southeast China (Guangdong, Guangxi, Hainan) and Indochina. Alpinia officinarum belongs to the Zingiberaceae family and is a perennial herb with thick, creeping reddish-brown rhizomes, lineolate acuminate ornamental leaves, and showy white flowers in racemes.
  • the extract of Alpinia officinarum is used in the treatment of rosacea.
  • the extract of Alpinia officinarum is an inhibitor of kallikrein-5 (KLK5).
  • the extract of Alpinia officinarum has been found to be able to treat increased vascularity, and in particular symptoms of rosacea, including inflammation and increased facial vascularity, with improved efficacy compared to conventional medications.
  • the extract of Alpinia officinarum has been found to be capable of blocking the activity or inhibiting the production of kallikrein-5 (KLK5), which consequently reduces and/or prevents the formation of LL-37 and abnormal peptide fragments, thereby inhibiting a major cascade of inflammation that has been found to be correlated with major clinical findings in rosacea.
  • KLK5 kallikrein-5
  • the extract of Alpinia officinarum preferably comprises one or more of: kaempferol, galangin, quercetin, pinocembrin, dihydrogalangin, 3-O-methylgalangin, 7-O-methylgalangin, kaempferide, 5- hydroxy-7-(4'-hydroxy-3'-methoxyphenyl)-l-phenyl-3-heptanone, 3,5-dihydroxy-l,7-bi-(3,4- dihydroxyphenyl)heptane, alpinin B, galangin 7-glucoside or any combination thereof.
  • the extract of Alpinia officinarum may be provided in the form of a cosmetic or pharmaceutical formulation for use in the treatment of increased facial vascularity, such as for example in the treatment of rosacea (e.g. in the treatment of symptoms associated with rosacea including for example inflammation and increased facial vascularity).
  • the extract is preferably an extract of the root of Alpinia officinarum.
  • a cosmetic or pharmaceutical formulation comprising a combination of at least two different components selected from: an extract of Alpinia officinarum, myricetin, lobaric acid, and an extract of Persicaria capitata (PCA).
  • the extract is preferably an extract of the root of Alpinia officinarum and/or Persicaria capitata.
  • the cosmetic or pharmaceutical formulation comprises an extract of Alpinia officinarum and myricetin.
  • the cosmetic or pharmaceutical formulation comprises an extract of Alpinia officinarum and lobaric acid.
  • the cosmetic or pharmaceutical formulation comprises an extract of Alpinia officinarum, and an extract of Persicaria capitata.
  • the cosmetic or pharmaceutical formulation comprises myricetin and lobaric acid.
  • the cosmetic or pharmaceutical formulation comprises lobaric acid and an extract of Persicaria capitata.
  • the cosmetic or pharmaceutical formulation comprises myricetin and an extract of Persicaria capitata.
  • a cosmetic or pharmaceutical formulation as herein described in the treatment of skin inflammation, preferably in the treatment of increased facial vascularity, such as for example in the treatment of rosacea.
  • the cosmetic or pharmaceutical formulation as herein described is used as a kallikrein-5 (KLK5) inhibitor.
  • KLK5 kallikrein-5
  • a method for the production of a cosmetic or pharmaceutical formulation as herein described comprising: obtaining at least two sources of at least two different components selected from: an extract of Alpinia officinarum, myricetin, lobaric acid, and an extract of Persicaria capitata; and combining the at least two components to provide a cosmetic or pharmaceutical formulation.
  • a kit for the production of a cosmetic or pharmaceutical formulation as described herein comprising: at least two sources of at least two different components selected from: an extract of Alpinia officinarum, myricetin, lobaric acid, and an extract of Persicaria capitata.
  • Figures 1A-C illustrates the UFIPLC/Q-ToF-MS chromatograms of three extracts of Alpinia officinarum (ALO);
  • Figure 1A illustrates the UFIPLC/Q-ToF-MS chromatogram of a methanol extract of Alpinia officinarum (ALO);
  • Figure IB illustrates the UFIPLC/Q-ToF-MS chromatogram of a water extract of Alpinia officinarum (ALO).
  • Figure 1C illustrates the UHPLC/Q-ToF-MS chromatogram of an ethanol-water extract of Alpinia officinarum (ALO);
  • Figure 2 illustrates the UHPLC/Q-ToF-MS chromatogram of a methanol extract of Alpinia officinarum and the identified compounds within the extract;
  • Figure 3 is an isobologram illustrating model lines of synergism and antagonism
  • Figure 4 illustrates the percentage inhibition of the enzyme Kallikrein 5 by pure compounds and extracts
  • Figure 5 is an isobologram for formulations comprising a combination myricetin/A/p/n/a officinarum (ALO);
  • Figure 6 is an isobologram for formualtions comprising a combination of Alpinia officinarum (ALO) and Persicaria capitata (PCA);
  • ALO Alpinia officinarum
  • PCA Persicaria capitata
  • Figure 7 illustrates gene expression of AQP3, CASP14, and CLDN1 after 24h treatment of keratinocytes with IOmM myricetin. Treatment was compared to vehicle treated sample which was put to 1. Statistics were performed in PRISM 5 where Repeated measurement one-way ANOVA was used on the ACt values with Dunnett's post hoc test were p* ⁇ 0.05, p** ⁇ 0.01 and p*** ⁇ 0.001; Figure 8 illustrates anti-inflammatory activity in PAR2 induced proinflammatory IL-8 model using FlaCaT cells; and
  • Figure 9 illustrates myricetin anti-inflammatory activity in IL-lbeta induced inflammation model in dermal microvascular endothelial (DMVEC) cells.
  • the root of the plant material ( Alpinia officinarum) was extracted using three different solvents: methanol; water; and 50:50 ethanohwater mixture.
  • Table 1 shows the extraction yields of Alpinia officinarum using the three different solvents: Table 1
  • KLK5 Fluman tissue Kallikrein 5
  • hK5 also known as stratum corneum tryptic enzyme
  • KLK5 regulate cell shedding (desquamation) in conjunction with KLK7 and KLK14 given its ability to degrade proteins which form the extracellular component of cell junctions in the stratum corneum.
  • the activity of the enzyme KLK5 is measured by its ability to cleave the fluorogenic peptide substrate Boc-VPR-AMC.
  • the primary screening assays are performed according to the validated standard protocol i.e. SP-SR- 201-v3 for KLK5 enzyme inhibition Assay.
  • the combinations of active components within a formulation are performed according to the validated standard protocol i.e. SP-SR-234 for Isobologram Analysis.
  • the first step is to determine the IC 50 s of each of the individual active components (i.e. active component A and active component B) within the formulation of the present invention.
  • the additive isobole for 50% inhibition is then traced on Graph Pad Prism as shown in Figure 3.
  • the concentration of active component B that will give 50% inhibition is interpolated with a chosen concentration of active component A.
  • the combination of the two active components A and B at these concentrations needs to then be screened.
  • Figure 4 illustrates the % inhibition of Kallikrein 5 for a number of active components and plant extracts including lobaric acid, myricetin, Alpinia officinarum (ALO) and Persicaria capitata (PCA).
  • Lobaric acid, myricetin, Alpinia officinarum (ALO) and Persicaria capitata (PCA) were found to show a very good percentage inhibition of KLK5 and the IC 5 oS of each of these active components and extracts were determined and the results are shown in Table 4.
  • Example 4 Formulation comprising two active components: myricetin and an extract of Alpinia officinarum
  • the isobologram of Figure 5 shows that the IC 50 values for the inhibition of kallikrein-5 of a number of different formulations of the present invention comprising myricetin and an extract of Alpinia officinarum. It can be seen from the isobologram that the IC 50 values of the formulations of the present invention are below the additive isobole, and as such it can be seen that the formulations of the present invention comprising a combination of myricetin and an extract of Alpinia officinarum provide a synergistic effect on the KLK5 inhibition activity.
  • Example 5 Formulation comprising two active components: an extract of Alpinia officinarum and PCA
  • the isobologram of Figure 6 shows that the IC 50 values for the inhibition of kallikrein-5 of a number of different formulations of the present invention comprising an extract of Alpinia officinarum and PCA. It can be seen from the isobologram that the IC 50 values of the formulations of the present invention are below the additive isobole, and as such it can be seen that the formulations of the present invention comprising a combination of an extract of Alpinia officinarum and PCA provide a synergistic effect on the KLK5 inhibition activity.
  • Example 6 Formulations comprising two active components selected from lobaric acid together with either an extract of Alpinia officinarum; an extract of Persicaria capitata; or myricetin
  • ALO extract of Alpinia officinarum and
  • PCA Persicaria capitata
  • myricetin were found to provide higher than 50% inhibition of kallikrein-5.
  • formulations of the present invention comprising a combination of lobaric acid with an extract of Alpinia officinarum (ALO), an extract of Persicaria capitata or myricetin has a synergistic effect on the ability of the formulation to inhibit production of KLK5 as shown in Tables 5 and 6.
  • the extracts and formulations of Examples 3 to 6 have been found to produce improved inhibition of kallikrein-5, and to have a synergistic effect on the inhibition of kallikrein-5.
  • the extracts and formulations of the present invention have therefore been shown to have improved efficacy for the treatment of symptoms associated with rosacea, such as for example inflammation and increased facial vascularity.
  • Barrier genes that were analysed were OCLN, AQP3 CLDN1, IVL, CASP14, KRT1, KRT10, FLG, PNPLA and TJP1. qPCR was used to analyze the gene expression of barrier genes.
  • Human epidermal keratinocytes (KC) were cultured in 48-well plates and treated for 24h with actives before RNA extraction followed by cDNA synthesis and then qPCR was performed for the wanted genes.
  • GAPDH was used as the housekeeping gene.
  • FIG. 7 shows that treatment with myricetin (lOpm) after 24 hours upregulated three barrier genes (AQP3, CASP14 and CLDN1) which were statistically significant when compared to the vehicle treated samples. An increase in gene expression is indicative of improvement of skin barrier in the skin.
  • Example 8 Effect of Lobaric acid as an anti-inflammatory agent
  • TRPV1 is an important ion channel and it has been shown that it is overexpressed in sensitive skin. TRPV1 can be activated directly or indirectly via PAR2. Targeting TRPV1 via PAR2 can be done in vitro by using PAR2 specific agonistic peptide (SLIGKV-NH2) leading to inflammatory IL-8 secretion.
  • PAR2 specific agonistic peptide SLIGKV-NH2
  • the aim of the study was to induce inflammatory response by targeting PAR2 in HaCaT keratinocyte cell line and test the anti-inflammatory potential of Lobaric acid (L.A) to inhibit PAR2 driven IL-8.
  • L.A Lobaric acid
  • Figure 8 provides IL-8 ELISA results (of the following groups: UT (untreated), PAR2 Ago (PAR2 stimulation with agonistic peptide), PAR2 + Antago (control, to decrease PAR2 expression with antagonistic peptide pretreatment), PAR2 + Lobaric acid (L.A pretreatment prior to PAR2 stimulation)) which illustrate representative data of two identical independent experiments.
  • PAR 2 induces IL-8 upregulation in HaCaT cells and the positive control PAR2 antagonist peptide significantly down regulates it.
  • Lobaric acid significantly inhibited PAR2 induced IL-8 and therefore is considered to be useful in the treatment of sensitive skin associated with inflammation.
  • HMVEC Human microvascular endothelial cells
  • Figure 9 illustrates IL-8 ELISA results for the following groups: UT (untreated), IL-lb (recombinant IL- lb stimulation), IL-lb + M (IL-lb + Myricetin) induced with IL-lb.
  • IL-lb induces IL-8 upregulation in HMVEC and Myricetin pretreatment, significantly inhibits cytokine induction.
  • myricetin has been shown to be useful in the treatment of sensitive skin redness associated with proinflammatory cytokines.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Birds (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Botany (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne l'utilisation d'un extrait d'Alpinia officinarum dans le traitement d'une vascularité accrue du visage. La présente invention concerne également une formulation cosmétique ou pharmaceutique comprenant une association d'au moins deux constituants actifs différents choisis parmi : un extrait d'Alpinia officinarum, la myricétine, l'acide lobarique et un extrait de Persicaria capitata, et son utilisation dans le traitement d'une vascularité accrue du visage. La présente invention concerne également un procédé de production d'une formulation cosmétique ou pharmaceutique comprenant une association d'au moins deux constituants actifs différents choisis parmi : un extrait d'Alpinia officinarum, la myricétine, l'acide lobarique et un extrait de Persicaria capitata.
EP20807385.8A 2019-12-23 2020-11-13 Extraits végétaux destinés au traitement d'une vascularité accrue du visage Pending EP4081181A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE1930415A SE544843C2 (en) 2019-12-23 2019-12-23 Plant extracts for treatment of rosacea
PCT/EP2020/082154 WO2021129977A1 (fr) 2019-12-23 2020-11-13 Extraits végétaux destinés au traitement d'une vascularité accrue du visage

Publications (1)

Publication Number Publication Date
EP4081181A1 true EP4081181A1 (fr) 2022-11-02

Family

ID=73449090

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20807385.8A Pending EP4081181A1 (fr) 2019-12-23 2020-11-13 Extraits végétaux destinés au traitement d'une vascularité accrue du visage

Country Status (4)

Country Link
EP (1) EP4081181A1 (fr)
CN (1) CN115209868A (fr)
SE (1) SE544843C2 (fr)
WO (1) WO2021129977A1 (fr)

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972993A (en) * 1998-03-20 1999-10-26 Avon Products, Inc. Composition and method for treating rosacea and sensitive skin with free radical scavengers
US7105172B1 (en) * 1999-11-18 2006-09-12 Bolla John D Treatment of rosacea
MXPA03009995A (es) * 2001-05-09 2004-06-30 Univ Michigan Uso de composiciones para tratar rosacea.
US20030105031A1 (en) * 2001-11-06 2003-06-05 Rosenbloom Richard A. Methods for the treatment of skin disorders
US20050215635A1 (en) * 2004-03-08 2005-09-29 Rafi M Mohamed Diarylheptanoid compounds and uses thereof
BRPI0614162A2 (pt) * 2005-07-25 2016-11-22 Basf Ag dermocosmético, e, uso de um composto
CN101115493A (zh) * 2005-08-12 2008-01-30 河乃建仁 生发剂
JP2007186457A (ja) * 2006-01-13 2007-07-26 Ichimaru Pharcos Co Ltd トリプターゼ活性阻害剤およびその利用
US7381433B1 (en) * 2007-01-08 2008-06-03 Johnson & Johnson Consumer Companies, Inc. Compositions containing an extract of a primula denticulata and use thereof
KR101322495B1 (ko) * 2012-02-29 2013-10-28 경희대학교 산학협력단 로바릭산을 유효성분으로 포함하는 피부 미백용 조성물
WO2014037529A2 (fr) * 2012-09-07 2014-03-13 Analyticon Discovery Gmbh Composition antipelliculaire
CN106572967A (zh) * 2014-05-21 2017-04-19 奢弥联合化学有限公司 包含植物提取物的美白活性剂、其用途以及包含所述美白活性剂的组合物
KR102345428B1 (ko) * 2014-09-25 2022-01-03 주식회사 네이처인랩 극지 지의류 추출물을 함유하는 자외선 차단제 조성물 및 이를 함유하는 기능성 화장품
BR112017014379B1 (pt) * 2014-12-30 2021-03-02 Procaps S.A. composição para o tratamento de infecções causadas pelo acaro demodex spp
CN106039174A (zh) * 2016-07-07 2016-10-26 罗淇 一种治疗骨关节病的中药药酒
CN106821865A (zh) * 2017-03-25 2017-06-13 广州市聚吉科绿色化学共性技术研究院有限公司 一种抗衰老组合物及其应用
SE543379C2 (en) * 2018-12-21 2020-12-22 Oriflame Cosmetics Ag Composition and formulation comprising a Persicaria Capitata plant extract

Also Published As

Publication number Publication date
SE1930415A1 (en) 2021-06-24
SE544843C2 (en) 2022-12-13
WO2021129977A1 (fr) 2021-07-01
CN115209868A (zh) 2022-10-18

Similar Documents

Publication Publication Date Title
JP6215364B2 (ja) ＭＣ−１Ｒ、ＭＣ−２Ｒ、およびμオピオイド受容体調節
TWI355273B (en) Anti-aging preparation
US9114115B2 (en) Compositions for skin disease or disorders
KR20100132514A (ko) 혈관의 성숙화, 정상화 또는 안정화제 및 주름 방지·개선제
JP2015131838A (ja) パッシフロラ・アラタ（Ｐａｓｓｉｆｌｏｒａａｌａｔａ）の植物抽出物を調製するプロセス、並びに化粧品組成物及び医薬組成物における該抽出物の使用
US20140039204A1 (en) 7'-phloroeckol compound for hair proliferation and a cosmetic composition containing same
WO2012081370A1 (fr) Inhibiteur de l'activité de l'endothéline, et agent de blanchiment de la peau
CN116322730A (zh) 作为衰老治疗剂的包含水飞蓟提取物的组合物
US20170281500A1 (en) Vegfc production promoter
JP2004067634A (ja) 育毛素材及びそれを含有する皮膚外用剤
EP4081181A1 (fr) Extraits végétaux destinés au traitement d'une vascularité accrue du visage
KR20200049714A (ko) 두충나무 껍질 추출물을 함유하는 피부 쿨링 또는 피부 홍조 완화용 화장료 조성물
KR102477053B1 (ko) 자감초, 향부자 및 강황의 혼합 추출물을 유효성분으로 함유하는 화장료 조성물
Park et al. Effects of xanthium stramarium and psoralea corylifolia extracts combined with UVA1 irradiation on the cell proliferation and TGF-β1 expression of keloid fibroblasts
KR101799426B1 (ko) 적하수오 추출물을 함유하는 화장품 조성물
JP7471085B2 (ja) コレステロール合成促進剤
KR101769546B1 (ko) 다프닌을 포함하는 화장 조성물 및 그의 용도
TWI554521B (zh) 色素上皮衍生因子衍生之多胜肽於治療禿髮和／或毛髮脫色之用途
KR20170076206A (ko) 호랑가시나무 추출물을 함유하는 지방세포 분화 촉진용 조성물
JP2016079152A (ja) エストロゲン受容体β活性化剤
KR20170107331A (ko) 콜라겐 발현 촉진 및 주름개선에 효과가 있는 화장료 개발
TWI423811B (zh) 用於抗氧化、抑制基質金屬蛋白酶活性及／或生成、及／或抑制有絲分裂原活化蛋白激酶之磷酸化之大葉千斤拔萃取物及其用途
KR101984276B1 (ko) 베르베린 하이드로클로라이드를 유효성분으로 포함하는 체모성장 저해용 조성물
TWI748944B (zh) 基質金屬蛋白酶產生抑制劑
KR20220110218A (ko) 화장품 및 의약용 펩타이드 및 조성물

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220331

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)